Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis

Analysis (14 RCTs) found long-acting GLP-1 receptor agonists resulted in greater reductions in HbA1c (difference −6 mmol/mol [95% CI −10; −2], P=0.007), fasting plasma glucose (−0.7 mmol/L [−1.2; −0.3], P=0.007) and weight (−1.4 kg [−2.2; −0.6], P=0.002) v short-acting agonists.


Diabetes Care